A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.

Lymphoid-specific tyrosine phosphatase (LYP), a member of the protein tyrosine phosphatase (PTP) family of signaling enzymes, is associated with a broad spectrum of autoimmune diseases. Herein we describe our structure-based lead optimization efforts within a 6-hydroxy-benzofuran-5-carboxylic acid series culminating in the identification of compound 8b, a potent and selective inhibitor of LYP with a K(i) value of 110 nM and more than 9-fold selectivity over a large panel of PTPs. The structure of LYP in complex with 8b was obtained by X-ray crystallography, providing detailed information about the molecular recognition of small-molecule ligands binding LYP. Importantly, compound 8b possesses highly efficacious cellular activity in both T- and mast cells and is capable of blocking anaphylaxis in mice. Discovery of 8b establishes a starting point for the development of clinically useful LYP inhibitors for treating a wide range of autoimmune disorders.

[1]  T. Hunter.  Tyrosine phosphorylation: thirty years and counting. , 2009, Current opinion in cell biology.

[2]  Caty Chung,et al.  Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids. , 2011, Journal of medicinal chemistry.

[3]  B. Lie,et al.  LYP inhibits T cell activation when dissociated from CSK , 2012, Nature chemical biology.

[4]  Lutz Tautz,et al.  In Silico Screening for PTPN22 Inhibitors: Active Hits from an Inactive Phosphatase Conformation , 2009, ChemMedChem.

[5]  Y. Keng,et al.  Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B. , 2000, Journal of medicinal chemistry.

[6]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[7]  L. Diehl,et al.  PEST Domain-Enriched Tyrosine Phosphatase (PEP) Regulation of Effector/Memory T Cells , 2004, Science.

[8]  Caty Chung,et al.  Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype , 2011, J. Comput. Aided Mol. Des..

[9]  Zhon-Yin Zhang,et al.  Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. , 2002, Annual review of pharmacology and toxicology.

[10]  Z. Zhang,et al.  Protein tyrosine phosphatases: prospects for therapeutics. , 2001, Current opinion in chemical biology.

[11]  O. Kassel,et al.  Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP‐1 , 2001, The EMBO journal.

[12]  D. Gawkrodger,et al.  A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo , 2005, Genes and Immunity.

[13]  Kristin G Ardlie,et al.  Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. , 2004, American journal of human genetics.

[14]  M. Garabedian,et al.  PEST‐domain‐enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice , 2012, Allergy.

[15]  Wen Hwa Lee,et al.  Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome , 2009, Cell.

[16]  S. Hardy,et al.  Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.

[17]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[18]  Nicole R. Cunningham,et al.  T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse , 2011, The Journal of experimental medicine.

[19]  R. Chan,et al.  Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). , 2010, Journal of medicinal chemistry.

[20]  Adrian Vella,et al.  Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. , 2004, Diabetes.

[21]  Caty Chung,et al.  Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. , 2008, Bioorganic & medicinal chemistry letters.

[22]  Zhon-Yin Zhang,et al.  Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. , 2012, Bioorganic & medicinal chemistry.

[23]  G. Griffiths.  Secretory lysosomes - a special mechanism of regulated secretion in haemopoietic cells. , 1996, Trends in cell biology.

[24]  A. Alonso,et al.  Aurintricarboxylic Acid Blocks in Vitro and in Vivo Activity of YopH, an Essential Virulent Factor of Yersinia pestis, the Agent of Plague* , 2003, Journal of Biological Chemistry.

[25]  Andy Hudmon,et al.  Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases , 2007, Proceedings of the National Academy of Sciences.

[26]  A. Weiss,et al.  Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line , 1984, The Journal of experimental medicine.

[27]  Tomas Mustelin,et al.  Characterization of TCR‐induced receptor‐proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP , 1999, European journal of immunology.

[28]  P. Concannon,et al.  Genetic Variation in PTPN22 Corresponds to Altered Function of T and B Lymphocytes1 , 2007, The Journal of Immunology.

[29]  N. Bottini,et al.  A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. , 2008, Human molecular genetics.

[30]  R. Spritz,et al.  PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. , 2008, The Journal of investigative dermatology.

[31]  F. Cozzolino,et al.  Functional characterization of an antigen involved in an early step of T-cell activation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Zheng,et al.  PTPN22 Silencing in the NOD Model Indicates the Type 1 Diabetes–Associated Allele Is Not a Loss-of-Function Variant , 2013, Diabetes.

[33]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[34]  G. Crabtree,et al.  Identification of a putative regulator of early T cell activation genes. , 1988, Science.

[35]  S. Bischoff.  Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data , 2007, Nature Reviews Immunology.

[36]  J. Tuckermann,et al.  Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. , 2007, Molecular endocrinology.

[37]  E. Shaoul,et al.  Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. , 1999, Blood.

[38]  D S Lawrence,et al.  Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition. , 2000, Biochemistry.

[39]  Nunzio Bottini,et al.  Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant , 2005, Nature Genetics.

[40]  D. Metcalfe,et al.  Understanding the mechanisms of anaphylaxis , 2008, Current opinion in allergy and clinical immunology.

[41]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[42]  N. Bottini,et al.  Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase. , 2010, Journal of inorganic biochemistry.

[43]  E. L. Luning Prak,et al.  Altered B Cell Homeostasis Is Associated with Type I Diabetes and Carriers of the PTPN22 Allelic Variant , 2012, The Journal of Immunology.

[44]  Steven R. Williams,et al.  Identification of Substrates of Human Protein-tyrosine Phosphatase PTPN22* , 2006, Journal of Biological Chemistry.

[45]  Dario R Alessi,et al.  Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.

[46]  Garth L Burn,et al.  Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? , 2011, FEBS letters.

[47]  N. Bottini,et al.  Role of PTPN22 in type 1 diabetes and other autoimmune diseases. , 2006, Seminars in immunology.

[48]  S. Waldvogel,et al.  High‐Yielding Cleavage of (Aryloxy)acetates , 2008 .

[49]  K. Berger,et al.  The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. , 2009, Human immunology.

[50]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[51]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[52]  T. Habib,et al.  Cutting Edge: The PTPN22 Allelic Variant Associated with Autoimmunity Impairs B Cell Signaling1 , 2009, The Journal of Immunology.

[53]  Steven J. Schrodi,et al.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. , 2004, American journal of human genetics.

[54]  D. Metcalfe,et al.  Mast cell biology: introduction and overview. , 2011, Advances in experimental medicine and biology.

[55]  Steven J. Schrodi,et al.  PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. , 2005, American journal of human genetics.

[56]  J. Cloutier,et al.  Cooperative Inhibition of  T-Cell Antigen Receptor Signaling by a Complex between a Kinase and a Phosphatase , 1999, The Journal of experimental medicine.

[57]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[58]  D S Lawrence,et al.  Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Jie Xu,et al.  Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold. , 2013, Journal of medicinal chemistry.

[60]  N. Bottini,et al.  Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes. , 2009, Journal of medicinal chemistry.

[61]  J. Jais,et al.  Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis , 2006, Annals of neurology.

[62]  Nunzio Bottini,et al.  Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. , 2011, Journal of medicinal chemistry.

[63]  E. Wagner,et al.  The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. , 1996, Nucleic acids research.